Estimation of Input Costs for a Markov Model in a German Health Economic Evaluation of Newer Antidepressants
Open Access
- 10 January 2018
- journal article
- research article
- Published by SAGE Publications in MDM Policy & Practice
- Vol. 3 (1)
Abstract
Background: Estimating input costs for Markov models in health economic evaluations requires health state–specific costing. This is a challenge in mental illnesses such as depression, as interventions are not clearly related to health states. We present a hybrid approach to health state–specific cost estimation for a German health economic evaluation of antidepressants. Methods: Costs were determined from the perspective of the community of persons insured by statutory health insurance (“SHI insuree perspective”) and included costs for outpatient care, inpatient care, drugs, and psychotherapy. In an additional step, costs for rehabilitation and productivity losses were calculated from the societal perspective. We collected resource use data in a stepwise hierarchical approach using SHI claims data, where available, followed by data from clinical guidelines and expert surveys. Bottom-up and top-down costing approaches were combined. Results: Depending on the drug strategy and health state, the average input costs varied per patient per 8-week Markov cycle. The highest costs occurred for agomelatine in the health state first-line treatment (FT) (“FT relapse”) with €506 from the SHI insuree perspective and €724 from the societal perspective. From both perspectives, the lowest costs (excluding placebo) were €55 for selective serotonin reuptake inhibitors in the health state “FT remission.” Conclusion: To estimate costs in health economic evaluations of treatments for depression, it can be necessary to link different data sources and costing approaches systematically to meet the requirements of the decision-analytic model. As this can increase complexity, the corresponding calculations should be presented transparently. The approach presented could provide useful input for future models.Keywords
This publication has 16 references indexed in Scilit:
- Methodologies used in cost-effectiveness models for evaluating treatments in major depressive disorder: a systematic reviewCost Effectiveness and Resource Allocation, 2012
- Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland☆Journal of Affective Disorders, 2010
- Design and Analysis Issues for Economic Analysis Alongside Clinical TrialsMedical Care, 2009
- When is Pharmacogenetic Testing for Antidepressant Response Ready for the Clinic? A Cost-effectiveness Analysis Based on Data from the STAR*D StudyNeuropsychopharmacology, 2009
- The cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorderInternational Journal Of Clinical Practice, 2008
- Cost-effectiveness as an outcome in randomized clinical trialsClinical Trials, 2006
- Model to assess the cost-effectiveness of new treatments for depressionInternational Journal of Technology Assessment in Health Care, 2006
- A clinical- and cost-effectiveness comparison of venlafaxine and selective serotonin reuptake inhibitors (SSRIs) in the management of patients with major depressive disorder from the perspective of an Austrian sickness fundJournal of Medical Economics, 2004
- An Introduction to Markov Modelling for Economic EvaluationPharmacoEconomics, 1998
- Markov Models in Medical Decision MakingMedical Decision Making, 1993